Innovating Works

MOLMED

Desconocido
EURE-CART: EURopean Endeavour for Chimeric Antigen Receptor Therapies MOLECULAR MEDICINE SPA tramitó un H2020: H2020-SC1-2016-2017 Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently availa...
2016-12-05 - 2021-06-30 | Financiado
CELL-PID: Advanced Cell based Therapies for the treatment of Primary ImmunoDeficiency MOLECULAR MEDICINE SPA participó en un FP7: Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity...
Financiado
OPTISTEM: Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases MOLECULAR MEDICINE SPA participó en un FP7: This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia...
Financiado
ATTRACT: Advanced Teaching and TRaining for Adoptive Cell Therapy MOLECULAR MEDICINE SPA participó en un FP7: Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practit...
Financiado
PERSIST: Persisting Transgenesis MOLECULAR MEDICINE SPA participó en un FP7: For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and,...
Financiado
SUPERSIST: Towards clinical translation of new gene targeting technologies for correcting inherited mutations a... MOLECULAR MEDICINE SPA participó en un FP7: Substantial evidence supports the therapeutic potential of ex vivo gene therapy based on Hematopoietic Stem Cell (HSC) or T lymphocytes to t...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.